Pharmacokinetics of Antibiotics During Extracorporeal Membrane Oxygenation (ECMO) Support
Overview
- Phase
- Not Applicable
- Intervention
- piperacillin-tazobactam
- Conditions
- Drug Effect
- Sponsor
- Boston Children's Hospital
- Enrollment
- 4
- Locations
- 1
- Primary Endpoint
- Plasma concentration: cefazolin
- Status
- Terminated
- Last Updated
- 4 years ago
Overview
Brief Summary
This study will measure plasma concentrations of piperacillin-tazobactam and cefazolin in pediatric patients supported with extracorporeal membrane oxygenation (ECMO) aiming to better understand the pharmacokinetics of these medications in this in vivo setting.
Investigators
Katie Moynihan
Cardiac Intensivist
Boston Children's Hospital
Eligibility Criteria
Inclusion Criteria
- •supported on ECMO
- •receive piperacillin-tazobactam or cefazolin as part of routine care or infection management
Exclusion Criteria
- •\>= 18 years
- •No Consent provided
Arms & Interventions
Pediatric patients supported on ECMO
Intervention: piperacillin-tazobactam
Pediatric patients supported on ECMO
Intervention: Cefazolin
Outcomes
Primary Outcomes
Plasma concentration: cefazolin
Time Frame: Peri drug dose administration until cessation of antibiotic therapy or cessation of ECMO support up to a maximum of 4 weeks.
Drug levels will be checked at baseline followed by additional measurements after the dose based on the dosing intervals but anticipated to be 30, 60, 120, 360, 480 minutes after the dose. Dosing regime will be q8-12 hourly pending end organ function (at the discretion of the treating team). The study will be continued for the duration of the Antibiotic therapy whilst on ECMO support and for one set of samples following decannulation.
Plasma concentration: piperacillin-tazobactam
Time Frame: Peri drug dose administration until cessation of antibiotic therapy or cessation of ECMO support up to a maximum of 4 weeks.
Drug levels will be checked at baseline followed by additional measurements after the dose based on the dosing intervals but anticipated to be 30, 60, 120, 360, 480 minutes after the dose. Dosing regime will be q8-12 hourly pending end organ function (at the discretion of the treating team). The study will be continued for the duration of the Antibiotic therapy whilst on ECMO support and for one set of samples following decannulation.